Photodynamic Therapy Shows Benefit in BCG-Unresponsive NMIBC
Investigators reported 90- and 450-day complete response rates of 53% and 28%, respectively, according to interim results from a phase 2 trial.
Investigators reported 90- and 450-day complete response rates of 53% and 28%, respectively, according to interim results from a phase 2 trial.
There is an unmet need for systemic treatment options in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based neoadjuvant chemotherapy, according to investigators.
Receipt of neoadjuvant vs adjuvant chemotherapy did not differ significantly by clinical nodal stage.
Acute kidney injury frequently occurs during neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer.
Management of metastatic renal cell carcinoma should be highly individualized, according to investigators.
In the VHA system, use of doublet therapy increased to more than 50% of mHSPC cases since 2020.
New study corroborates findings from a prior study of men receiving care in the Veterans Health Administration system.
As far as investigators are aware, their study is the first randomized controlled trial comparing radical prostatectomy and stereotactic body radiation therapy.
Partial gland ablation of MRI-invisible prostate cancer has been controversial.
The 5-year metastasis-free survival was similar with trimodal therapy and radical cystectomy.